#treatment

Study finds that Cabenuva administered every other month maintains viral suppression for two years.

The number of days to an undetectable viral load dropped by nearly two weeks, but there’s more work to do.

Ask POZ is an ongoing section on POZ.com dedicated to answering general wellness questions.

If left untreated, hepatitis B and C can lead to cirrhosis and liver cancer.

A new CDC model shows that more treatment and less PrEP Would slash new HIV cases by 94%.

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

Lenacapavir shows promise for long-acting HIV treatment and prevention.

An Argentine woman appears to be free of HIV long after stopping treatment.

Here’s a closer look at some of the available COVID-19 treatments and how to get more information about them and others.

Switching to an integrase inhibitors is not tied to gain in bad fat, according to recent study.

People with untreated HIV in a recent study had signs of faster cell aging, which treatment reduced but did not eliminate.

HIV organizations and groups look forward to 2021 and closing in on the goal of ending HIV.

A small subset of people living with HIV are able to control viral replication without antiretroviral treatment.

While people with HIV have a higher rate of early Alzheimer’s than those without the virus, treatment appears to eliminate this excess risk.

A recent study sheds light on weight gain after switching to new form of tenofovir.

Findings confirm that Trogarzo maintains viral load suppression for nearly 10 years.